Michael Joseph LUZZIO,Julien PAPILLON,Michael Scott VISSER
申请号：
US15830769
公开号：
US20180179181A1
申请日:
2017.12.04
申请国别(地区):
US
年份:
2018
代理人:
摘要：
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
